Detail

Study ID: AstraZeneca D933SC00001 NILE

Title:

A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

Description:
Title: Patients who are diagnosed with unresectable Stage III and Stage IV Uothelial/Bladder Cancer are 18 years or older, never received cancer treatment or recurrent disease that has received treatment more than 12 months ago are invited to join this clinical trial. Description: The purpose of the study is to find effective treatment for bladder cancer.
Location:
Sioux Falls Region
Principal Investigator:
Christopher Sumey, MD
Disease:
Other
Stage:
Phase III
Status:
Active - Open to Accrual